Lee Kevin 4
4 · BICYCLE THERAPEUTICS PLC · Filed Apr 6, 2026
Research Summary
AI-generated summary of this filing
Bicycle Therapeutics (BCYC) CEO Kevin Lee Sells Shares
What Happened
Kevin Lee, CEO of Bicycle Therapeutics (BCYC), disposed of a total of 7,683 shares in two open-market sales to satisfy tax withholding on vested RSUs. On 2026-04-02 he sold 5,967 shares at a weighted average price of $4.91 for proceeds of $29,298 (prices ranged $4.88–$4.98). On 2026-04-06 he sold 1,716 shares at a weighted average price of $5.05 for proceeds of $8,666 (prices ranged $5.03–$5.05). Combined proceeds were approximately $37,964. These sales were "sell-to-cover" transactions required by the award agreement and are not presented as discretionary sales.
Key Details
- Transaction dates and prices:
- 2026-04-02: 5,967 shares sold, weighted avg $4.91 (range $4.88–$4.98) — $29,298
- 2026-04-06: 1,716 shares sold, weighted avg $5.05 (range $5.03–$5.05) — $8,666
- Total shares sold: 7,683; total gross proceeds: ~$37,964.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnotes of note:
- F1: Sales were mandated "sell to cover" to satisfy statutory tax withholding on RSU vesting (not discretionary).
- F2/F3: Reported prices are weighted averages; multiple trade prices within the ranges above.
- Filing: Form 4 filed 2026-04-06 reporting the above transactions. The filing does not indicate a late report.
Context
"Sell-to-cover" transactions are common when restricted stock units vest and employers or award agreements require taxes be paid by selling a portion of shares; such sales are administrative and do not necessarily signal the insider's view on the company's prospects.
Insider Transaction Report
- Sale
Ordinary Shares
[F1][F2]2026-04-02$4.91/sh−5,967$29,298→ 613,029 total - Sale
Ordinary Shares
[F1][F3]2026-04-06$5.05/sh−1,716$8,666→ 611,313 total
Footnotes (3)
- [F1]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.88 to $4.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.05 inclusive.